Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

ParkDB: a Parkinson's disease gene expression database.

Taccioli C, Tegnér J, Maselli V, Gomez-Cabrero D, Altobelli G, Emmett W, Lescai F, Gustincich S, Stupka E.

Database (Oxford). 2011 May 18;2011:bar007. doi: 10.1093/database/bar007. Print 2011.

2.

Parkinson's disease: mechanisms and models.

Dauer W, Przedborski S.

Neuron. 2003 Sep 11;39(6):889-909. Review.

3.

PDbase: a database of Parkinson's disease-related genes and genetic variation using substantia nigra ESTs.

Yang JO, Kim WY, Jeong SY, Oh JH, Jho S, Bhak J, Kim NS.

BMC Genomics. 2009 Dec 3;10 Suppl 3:S32. doi: 10.1186/1471-2164-10-S3-S32.

4.

Gene expression profiling of substantia nigra dopamine neurons: further insights into Parkinson's disease pathology.

Simunovic F, Yi M, Wang Y, Macey L, Brown LT, Krichevsky AM, Andersen SL, Stephens RM, Benes FM, Sonntag KC.

Brain. 2009 Jul;132(Pt 7):1795-809. doi: 10.1093/brain/awn323. Epub 2008 Dec 3.

5.

Parkinson's disease candidate gene prioritization based on expression profile of midbrain dopaminergic neurons.

Vahedi S, Rajabian M, Misaghian A, Grbec D, Simon HH, Alavian KN.

J Biomed Sci. 2010 Aug 17;17:66. doi: 10.1186/1423-0127-17-66.

6.

Analysis of gene expression in Parkinson's disease: possible involvement of neurotrophic support and axon guidance in dopaminergic cell death.

Bossers K, Meerhoff G, Balesar R, van Dongen JW, Kruse CG, Swaab DF, Verhaagen J.

Brain Pathol. 2009 Jan;19(1):91-107. doi: 10.1111/j.1750-3639.2008.00171.x. Epub 2008 May 7.

PMID:
18462474
7.

Surprising behavioral and neurochemical enhancements in mice with combined mutations linked to Parkinson's disease.

Hennis MR, Marvin MA, Taylor CM 2nd, Goldberg MS.

Neurobiol Dis. 2014 Feb;62:113-23. doi: 10.1016/j.nbd.2013.09.009. Epub 2013 Sep 26.

8.

The impact of reactive oxygen species and genetic mitochondrial mutations in Parkinson's disease.

Zuo L, Motherwell MS.

Gene. 2013 Dec 10;532(1):18-23. doi: 10.1016/j.gene.2013.07.085. Epub 2013 Aug 15. Review.

PMID:
23954870
9.

Current status and future directions of gene expression profiling in Parkinson's disease.

Greene JG.

Neurobiol Dis. 2012 Jan;45(1):76-82. doi: 10.1016/j.nbd.2010.10.022. Epub 2010 Nov 5. Review.

11.

The medial and lateral substantia nigra in Parkinson's disease: mRNA profiles associated with higher brain tissue vulnerability.

Duke DC, Moran LB, Pearce RK, Graeber MB.

Neurogenetics. 2007 Apr;8(2):83-94. Epub 2007 Jan 9.

PMID:
17211632
12.

The intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a new rodent model to test palliative and neuroprotective agents for Parkinson's disease.

Prediger RD, Aguiar AS Jr, Moreira EL, Matheus FC, Castro AA, Walz R, De Bem AF, Latini A, Tasca CI, Farina M, Raisman-Vozari R.

Curr Pharm Des. 2011;17(5):489-507. Review.

PMID:
21375482
13.

Subthalamic GAD gene transfer in Parkinson disease patients who are candidates for deep brain stimulation.

During MJ, Kaplitt MG, Stern MB, Eidelberg D.

Hum Gene Ther. 2001 Aug 10;12(12):1589-91.

PMID:
11529246
14.

Disease duration and the integrity of the nigrostriatal system in Parkinson's disease.

Kordower JH, Olanow CW, Dodiya HB, Chu Y, Beach TG, Adler CH, Halliday GM, Bartus RT.

Brain. 2013 Aug;136(Pt 8):2419-31. doi: 10.1093/brain/awt192.

15.

n-butylidenephthalide protects against dopaminergic neuron degeneration and α-synuclein accumulation in Caenorhabditis elegans models of Parkinson's disease.

Fu RH, Harn HJ, Liu SP, Chen CS, Chang WL, Chen YM, Huang JE, Li RJ, Tsai SY, Hung HS, Shyu WC, Lin SZ, Wang YC.

PLoS One. 2014 Jan 8;9(1):e85305. doi: 10.1371/journal.pone.0085305. eCollection 2014.

16.

MDPD: an integrated genetic information resource for Parkinson's disease.

Tang S, Zhang Z, Kavitha G, Tan EK, Ng SK.

Nucleic Acids Res. 2009 Jan;37(Database issue):D858-62. doi: 10.1093/nar/gkn770. Epub 2008 Oct 23.

17.

Gene expression profiling in progressively MPTP-lesioned macaques reveals molecular pathways associated with sporadic Parkinson's disease.

Ohnuki T, Nakamura A, Okuyama S, Nakamura S.

Brain Res. 2010 Jul 30;1346:26-42. doi: 10.1016/j.brainres.2010.05.066. Epub 2010 Jun 1.

PMID:
20513370
18.

Elevated alpha-synuclein mRNA levels in individual UV-laser-microdissected dopaminergic substantia nigra neurons in idiopathic Parkinson's disease.

Gründemann J, Schlaudraff F, Haeckel O, Liss B.

Nucleic Acids Res. 2008 Apr;36(7):e38. doi: 10.1093/nar/gkn084. Epub 2008 Mar 10.

19.

PGC-1α, a potential therapeutic target for early intervention in Parkinson's disease.

Zheng B, Liao Z, Locascio JJ, Lesniak KA, Roderick SS, Watt ML, Eklund AC, Zhang-James Y, Kim PD, Hauser MA, Grünblatt E, Moran LB, Mandel SA, Riederer P, Miller RM, Federoff HJ, Wüllner U, Papapetropoulos S, Youdim MB, Cantuti-Castelvetri I, Young AB, Vance JM, Davis RL, Hedreen JC, Adler CH, Beach TG, Graeber MB, Middleton FA, Rochet JC, Scherzer CR; Global PD Gene Expression (GPEX) Consortium.

Sci Transl Med. 2010 Oct 6;2(52):52ra73. doi: 10.1126/scitranslmed.3001059.

20.

Robust dysregulation of gene expression in substantia nigra and striatum in Parkinson's disease.

Miller RM, Kiser GL, Kaysser-Kranich TM, Lockner RJ, Palaniappan C, Federoff HJ.

Neurobiol Dis. 2006 Feb;21(2):305-13. Epub 2005 Sep 6.

PMID:
16143538
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk